Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

7.4%

10 terminated/withdrawn out of 135 trials

Success Rate

79.2%

-7.3% vs industry average

Late-Stage Pipeline

20%

27 trials in Phase 3/4

Results Transparency

18%

7 of 38 completed trials have results

Key Signals

28 recruiting7 with results7 terminated

Enrollment Performance

Analytics

Phase 1

57(42.5%)

Phase 2

47(35.1%)

Phase 3

27(20.1%)

N/A

3(2.2%)

134Total

Phase 1(57)

Phase 2(47)

Phase 3(27)

N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (135)

Showing 20 of 135 trials

NCT07503756Phase 2Recruiting

JS212 Combination Therapies in Metastatic Colorectal Cancer

Role: lead

NCT07484724Phase 2Recruiting

A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma

Role: lead

NCT04085276Phase 3Completed

Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment

Role: lead

NCT07045311Phase 2Recruiting

JS207 Combination Therapy in Triple-negative Breast Cancer

Role: lead

NCT04848753Phase 3Active Not Recruiting

Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Role: lead

NCT07518160Phase 2Not Yet Recruiting

JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study

Role: lead

NCT07480733Phase 2Not Yet Recruiting

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

Role: lead

NCT05798845Phase 2Recruiting

The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer

Role: collaborator

NCT05888402Phase 2Active Not Recruiting

Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC

Role: collaborator

NCT06924606Phase 2Recruiting

Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy

Role: lead

NCT07284134Phase 3Recruiting

JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.

Role: lead

NCT07309276Phase 2Not Yet Recruiting

A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer

Role: lead

NCT06732973Phase 1Completed

A Bioequivalence Study of JS005 Pre-filled Syringe and JS005 Auto-injector

Role: lead

NCT05975268Phase 3Completed

A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis

Role: lead

NCT04523493Phase 3Active Not Recruiting

Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC

Role: lead

NCT05427396Phase 1Terminated

A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors

Role: lead

NCT05618327Phase 1Active Not Recruiting

Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Role: lead

NCT05664971Phase 1Completed

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Role: lead

NCT04394975Phase 3Completed

Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer

Role: lead

NCT06882876Phase 1Enrolling By Invitation

JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study

Role: collaborator